Sign up USA
Proactive Investors - Run By Investors For Investors

Akers Biosciences Inc breakthrough device granted US patent

The protection covers the company’s PIFA Rapid Assay and the unique methods it uses for detecting platelet factor 4 antibodies.
Stylised picture of patent agreement plus padlock.
The US Patent and Trademark Offices has given its sign-off.

Akers Biosciences Inc (NASDAQ:AKER, LON:AKR) has been granted a US patent for the technology at the heart of a test that detects an allergy to the blood thinning drug Heparin.

The protection covers the company’s PIFA Rapid Assay and the unique methods it uses for detecting platelet factor 4 antibodies.

"This patent is particularly important because it protects the antigen that gives our tests their superior accuracy,” said chairman and co-founder Raymond Akers.

“With published studies that demonstrate that our tests never deliver a false positive result, we believe them to be the most accurate available way to rule out HIT."

The device takes 10 minutes to assess for heparin-induced thrombocytopenia, or HIT, where the blood clots instead of thins.

The process of assessing a patient for HIT requires expensive blood tests that can take several days to turn around.

The diagnostic is the only one of its kind to receive sign off from America’s all-powerful Food & Drug Administration.

Ian_55ae0ddd437b7.jpg
Why Invest In Akers Biosciences, Inc.? Read More Here

Register here to be notified of future AKR Company articles
View full AKR profile

Akers Biosciences, Inc. Timeline

Related Articles

cells_56ab78cfbeec5.jpg
January 29 2016
A return to Nasdaq and ongoing commercial success promises to address a significant disconnect in the valuation of Pressure Bioscience...
AZN3.jpg
March 23 2016
Douglas Carrara has joined as vice president of Global Marketing and Commercial Operations, while Tony Saporito has been brought in as vice president of US Sales and Distribution.
shutterstock_184785974.jpg
April 28 2016
Last year's acquisition of Kinesis Pharma meant that it could now offer a one-stop shop for its pharmaceuticals clients and expand its client base.
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC